Progenika Biopharma presents a biochip that guarantees safety in blood transfusions

Public release date: 4-Jul-2007
Contact: Irati Kortabitarte
iratik@elhuyar.com
34-943-363-040
Elhuyar Fundazioa

Progenika Biopharma presents a biochip that guarantees safety in blood transfusions

The Basque biotechnology company, Progenika Biopharma, devoted to research and development in personalised medicine, have presented a DNA biochip, known as BLOODchip, which greatly eliminates the risk of adverse reactions due to incompatibility in blood groups between donor and receptor in blood transfusions.

With the aim of guaranteeing safety during blood transfusions, Progenika has developed and validated 1,000 clinical samples in cooperation with the principal European blood banks. Concretely, the validation of these samples was 99.8%, considerably higher than that produced using the current serology technique, which produces an error of 3%.

Thus, BLOODchip is currently the safest and most precise technique for genetically determining blood groups, enabling the reduction of adverse reactions in blood transfusions.